General and administrative expenses were $10.6 million for the quarter ended September 30, 2024, compared to $6.0 million for the same period in 2023. The increase was primarily attributable to ...

Mizuho raised the firm’s price target on Alkermes (ALKS) to $40 from $35 and keeps an Outperform rating on the shares. The firm assessed ...

BMO Capital raised the firm’s price target on Schrodinger (SDGR) to $28 from $25 and keeps an Outperform rating on the shares. The ...

Prices will start in the mid-$40,000s for the entry-level RTL trim, but take a step up to the TrailSport and you’ll get the amber LED daytime running lights, plus off-road tuned suspension, steel skid ...

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that the first patient has been ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

The new Passport stands as Honda's most aggressive off-road SUV with a handsome redesign, rugged upgrades, and an optional ...

China’s upcoming H-20 Xi’an stealth bomber has the U.S. concerned, with capabilities that could rival the B-2 Spirit and even ...

Cambridge biopharma company Microbiotica reveals that the first patient has been dosed in its Phase 1b First-in-Human trial, ...

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...

"Within the next several quarters we expect meaningful data readouts on four clinical programs in our robust R&D pipeline that have the potential to significantly improve the lives of millions of ...